Table 1.
Pharmacokinetic parameters of Galeterone, VNPP414 and VNPP433-3β after intravenous (IV), intraperitoneal (IP), or oral (PO) administration in male CD-1 mice.
| Compounds | Dosing | AUC (0–∞) (ng.h/mL) |
Cmax (ng/mL) |
T1/2 (h) |
F (%) |
|---|---|---|---|---|---|
| Galeterone | IV (1 mg/kg) | 57.90 | - | 0.17 | - |
| IP (10 mg/kg) | 111.29 | 506.59 | 1.24 | 168.81 | |
| PO (10 mg/kg) | 969.07 | 32.8 | 1.26 | 18.44 | |
| VNPP414 | IV (1 mg/kg) | 547.43 | - | 7.48 | - |
| IP (10 mg/kg) | 8601.34 | 2174.37 | 6.25 | 157.12 | |
| PO (10 mg/kg) | 1030.00 | 175.40 | 4.30 | 19.35 | |
| VNPP433-3β | IV (1 mg/kg) | 3469.23 | - | 14.26 | - |
| IP (10 mg/kg) | 57290.45 | 2294.19 | 22.38 | 123.20 | |
| PO (10 mg/kg) | 31755.01 | 706.27 | 31.19 | 49.45 |
AUC(0–∞): area under the concentration-time curve from the time of dosing extrapolated to infinity; Cmax: maximum plasma concentration; T1/2: elimination half-life and F (%): absolute bioavailability.